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Abstract 
This thesis details the design, development and execution of innovative methodology in the 
total synthesis of the terpene-derived marine natural product, furospongolide. It also outlines 
the synthetic routes used to prepare a novel range of furanolipids derivatives and subsequent 
evaluation of their potential as antitumour agents. 
The first chapter is a review of the literature describing efforts undertaken towards the 
synthesis of biologically active furanosesterterpenoid marine natural products. A brief 
discussion on the sources and biological activity exhibited by furan natural products is also 
provided. In addition, a concise account of the role of hypoxia in cancer, and the increasing 
interest in HIF-1 inhibition as a target for chemotherapeutics is examined. 
The second chapter discusses the concise synthesis of the marine HIF-1 inhibitor 
furospongolide, which was achieved in five linear steps from (E,E)-farnesyl acetate. The 
synthetic strategy features a selective oxidation reaction, a Schlosser sp3-sp3 cross-coupling, 
a Wittig cross-coupling and an elaborate one-pot selective reduction, lactonisation and 
isomerization reaction to install the butenolide ring. The structure-activity relationship of 
furospongolide was also investigated. This involved the design and synthesis of a library of 
structurally modified analogues sharing the same C1-C13 subunit. This was achieved by 
exploiting the brevity and high level of convergence of our synthetic route together with the 
readily amenable structure of our target molecule. Exploiting the Schlosser cross-coupling 
allowed for replacement of furan with other heterocycles in the preparation of various 
furanolipid and thiophenolipid derivatives. The employment of reductive amination and 
Wittig chemistry further added to our novel library of structural derivatives.  
The third chapter discusses the results obtained from the NCI from biological evaluation 
From a collection of 28 novel compounds evaluated against the NCI-60 cancer cell array, six 
drug candidates were successfully selected for further biological evaluation on the basis of 
antitumour activity. COMPARE analysis revealed a strong correlation between some of our 
design analogues and the blockbuster anticancer agent tamoxifen, further supporting the 
potential of furanolipids in the treatment of breast cancer.  
The fourth chapter, details the full experimental procedures, including spectroscopic and 
analytical data for all the compounds prepared during this research.  
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“Live as if you were to die tomorrow. Learn as if you were to live forever.” 
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1.1 Background 
1.1.1 Overview 
The purpose of this introduction is to give a comprehensive overview on both the chemical 
and biological significance of furanolipids to modern day science. With respect to the latter, a 
furanolipid based natural product known as furospongolide was isolated from an Indonesian 
marine sponge and was found to possess promising antitumour activity towards the treatment 
of breast cancer. Today, furospongolide is recognised as a small molecule inhibitor of 
hypoxia-induced HIF-1 activation, which has recently become an attractive target for 
advanced stage cancer therapy. In this chapter, we will discuss the role of hypoxia in cancer, 
and the increasing interest in HIF-1 inhibition as a target for chemotherapeutics. In addition, 
we will examine recent advances in the discovery and development of small molecule 
inhibitors that target the HIF-1 pathways as potential antitumour agents.  
As furospongolide is a member of a large family of terpene-derived furanosesterterpenoids, 
we will be reviewing the literature describing efforts undertaken towards the synthesis of 
structurally related sesterterpenoids, focusing on completed total syntheses of biologically 
active marine natural products. This review will provide us with innovative methodology to 
achieve the concise total synthesis of furospongolide as well as promising concepts to alter 
its structure and increase its potency as an antitumour agent.  
We will begin this chapter by discussing the history of furan, its physical and chemical 
properties; traditional and modern methods towards the synthesis of this heterocycle as well 
as describing some diverse biologically active natural products containing furan(s).  
Chapter 1 Introduction 
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1.1.2 History of Furan 
The earliest furan compound discovered is pyromucic acid 1, more commonly known as 
furoic or furan-2-carboxylic acid (Figure 1.1). Pyromucic acid 1 was first isolated by Carl 
Wilhelm Scheele in 1780 by the dry distillation of mucic acid. In 1832 furfural 2, or furan-2-
carbaldehyde, was obtained by the action of sulfuric acid and manganese dioxide on sugar, 
but these furans were not related until 1860, when furfural 2 was oxidized to furoic acid 1 
with silver oxide (Scheme 1.1).1,2 Furan 3 itself was first prepared by Heinrich Limpricht in 
1870 by treating barium furoate with soda lime.3  
In 1922 furfural 2 became commercially available, economically and in large-scale quantities 
from Quaker Oats Company from the acid hydrolysis of cereal waste. At this time the outlets 
for furfural 2 was limited except for its occasional use in perfume, but its low cost and 
availability greatly stimulated the search for uses. Today furfural 2 is still produced from 
agricultural by-products like sugarcane bagasse and corncobs and is the usual starting 
material for commercial preparation of other simple furans. This industrially used method of 
preparation of furans is rare as it is based on a renewable starting material rather than on oil, 
gas, or coal.4-6  
Figure 1.1 
The positions in the furan ring are usually numbered, but in older literature a less convenient 
lettering system was sometimes used as illustrated in Figure 1.1. The compounds commonly 
known as furoic acid 1 and furfural 2 could therefore be named furan-2-carboxylic acid and 
furan-2-carbaldehyde respectively.1   
O
COOH
O
O
Furan-2-carboxylic acid Furan-2-carbaldehyde
1 2
O
1
2
34
5 (α)
(β)
(α')
(β')
Furan
3
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1.1.3 Physical properties of furan 
Furan 3 itself is a colourless, volatile and highly flammable oil (b.p. 31-36 oC), which is 
slightly soluble in water and miscible with most organic solvents. The arrangement of the 
atoms in the ring was proved by Baeyer in 1877 following the conversion of furfural 2 into 
furan 3 as exemplified in Scheme 1.1.1 
 
 
 
Scheme 1.1 
 
Furan cannot be accurately represented by classical structure 3, as it is best considered as a 
resonance hybrid of the formulae 3a-3d. The furan molecule is far from a regular pentagon in 
shape and the bond lengths suggest that structure 3 is the major contributor to the resonance 
hybrid (Figure 1.2).1  
 
 
 
Figure 1.2 
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1.1.4 Chemical properties of furan 
Furan 3 and thiophene 4 can usefully be examined in parallel, comparing one with the other 
and with pyrrole.7 Furan 3 is an electron-rich heterocycle and is generally less reactive than 
pyrrole towards electrophiles (by a factor of about 105) although it is still much more reactive 
than benzene. Although furan 3 clearly exhibits aromatic stabilisation, its resonance energy 
(~16 kcal/mol) is significantly less than that of benzene (~36 kcal/mol), and thus it can be 
converted to non-aromatic derivatives under fairly mild conditions (most like a 1,3-diene). In 
the trio of heteroaromatic systems, furan 3 is much less aromatic than pyrrole (~22 kcal/mol) 
and thiophene 4 (~30 kcal/mol) is the most synthetically flexible of the aromatic heterocycles. 
For example, thiophene 4 undergoes normal nitration, with selectivity for α-substitution (5) 
rather than β-substitution (6) similar to pyrrole. In contrast, furan 3 tends to produce 2,5-
dihydrofuran adducts (stable isolatable intermediate) in which the elements of the attacking 
agent have added to the heterocycle with subsequent loss of aromaticity. The aromatic 
substitution product 7 can be easily obtained from the adduct by base-induced loss of acetic 
acid as shown in Scheme 1.2.1,6,7 Nitration of furan illustrates how both addition-elimination 
and normal substitution mechanisms can operate together.  
Scheme 1.2: Nitration of thiophene and furan using acetyl nitrate. 
One attribute that makes furan 3 such a useful building block is its ability to undergo a wide 
range of reactions and serve as a precursor to many important substructures (Scheme 1.3). 
Combined with its easy accessibility and its unique reactivity, furan 3 has achieved a 
prominent role in synthetic chemistry. 
S S
NO2
S
NO2
6:1
O O
HNO3, Ac2O
HNO3, Ac2O H
NO2 OAcO
H H
NO2
+ AcO
O
NO2
2,5-dihydrofuran adduct
Pyridine
− AcOH
4 5 6
3 7
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Scheme 1.3 
The ring of furan 3 is opened easily by acids and can be hydrolysed under acidic conditions 
to give the saturated dicarbonyl derivative 8. Furan 3 can be converted to alcohol 9 through a 
Vilsmeier-Haack reaction followed by subsequent reduction. Furan 3 is susceptible to 
reduction and oxidation reactions and can provide the unsaturated dialdehyde 12 by oxidative 
cleavage with meta-chloroperbenzoic acid. The cycloaddition of furan 3 with singlet oxygen 
gives cyclic peroxides, which break down with loss of carbon dioxide revealing five-
membered lactones (10), which are a very common occurrence in nature and are usually 
referred to as butenolides. Catalytic hydrogenation of furan leads to the formation of 
tetrahydrofuran derivatives (11), which are also common features in a vast array of natural 
products. Furan 3 reacts rapidly with bromine in dioxane at 0 oC to form 2-bromofuran 13. 
However, if a nucleophilic solvent like methanol was employed, furan can be oxidised to a 
stable adduct, 2,5-dihydro-2,5-dimethoxyfuran 14 resulting from nucleophilic displacement 
of the bromide.7 Furan 3 is the least aromatic 5-membered ring and therefore reacts readily 
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with electron-deficient dienophiles to afford oxabicyclo[2.2.1]heptane derivatives (19). Furan 
also participates in [4+3] cycloadditions with oxyallyl cations to give 
oxabicyclo[3.2.1]octane derivatives (18). In furan 3, the 2 and 5 positions are the sites of 
maximum π-electron density as a result of electron donation from the heteroatom and 
consequently they are the favoured positions for sulfonylation (17), acetylation (15), 
metallation (20) and condensation reactions (9) (Scheme 1.3).   
1.1.5 Synthesis of furans and thiophenes 
Numerous routes have been developed for the ring synthesis of thiophenes and furans. With 
respect to the latter, two classical methods of furan ring synthesis are the Paal-Knorr 
synthesis and the Feist-Benary synthesis (Figure 1.3). 
Figure 1.3 
One of the most important methods in organic chemistry for the synthesis of furans, 
thiophenes and pyrroles from 1,4-dicarbonyl compounds through a dehydration reaction is 
known as a Paal-Knorr synthesis. Although the Paal-Knorr synthesis has seen widespread 
use, the mechanism wasn’t fully understood until it was elucidated by van Amarnath et al. in 
the 1995.8 The most likely sequence has intramolecular addition of enolic oxygen to the other 
carbonyl group requiring, loss of water to provide furan 24. 1,4-Diketones 23 can be obtained 
in several ways; the alkylation of a 1,3-keto-ester 22 with α-haloketone 21 is one such 
method as demonstrated below in Scheme 1.4. 
X XX
Paal-Knorr synthesisFeist-Benary synthesis X = S or O
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Scheme 1.4: Paal Knorr synthesis. 
The synthetic strategy for the preparation of the thiophene ring through Paal Knorr 
methodology first involves exposure of an appropriate 1,4-dicarbonyl precursor to conditions 
that convert a carbonyl group into a thiocarbonyl group (25-26). The reagent of choice for 
this transformation is Lawesson’s reagent as it is more soluble in organic solvents than 
traditional thionation reagents like phosphorous pentasulfide. To date there is still confusion 
whether both carbonyl groups are converted, but exactly comparable sequences lead to the 
aromatic thiophene 27, with loss of H2S (if both have been thionated) or H2O (if one has been 
thionated) (Scheme 1.5).7  
Scheme 1.5 
Br
MeO MeO
CO2Me
O O
CO2Me
MeMe
NaOMe, 0 oC
(CO2H)2, Δ
OH O
MeMe
O
OH
Me
Me
H+
O
Me Me
CO2Me
21 22 23
24
CO2Me CO2MeH
- H2O
O O
MePh
S S
MePh
SH S
Ph Me
H+
S
SH
Me
PhS
MePh
− H2S
Lawesson's 
reagent
 Δ
25 26
27
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Conversely, the Feist-Benary synthesis occurs when an α-halocarbonyl reacts with a β-
dicarbonyl in the presence of base. The resulting product is a 3-furoate that incorporates 
substituents present in both starting materials (Scheme 1.6).5,6,9,10  
Scheme 1.6: Feist-Benary synthesis. 
A common use of the Feist-Benary furan synthesis is for the preparation of 2-substituted-3-
furoates. The most popular synthetic target is the furan originally prepared by Benary et al., 
namely ethyl 2-methyl-3-furoate (R1 and R3 = H; R2 = Me; R4 = Et, Scheme 1.6).11 Although 
the Paal-Knorr synthesis and the Feist-Benary have proven very useful for the synthesis of 
furan derivatives, there are some limitations, including the difficulty in accessing furans that 
contain sensitive functional groups (unstable to basic conditions) and the inability to provide 
furans with high flexibility regarding their substitution pattern. For this reason, the 
development of innovative and more efficient methods for the synthesis of highly 
functionalized furans under milder conditions remains an area of on-going interest.  
Functionalised furans are frequent subunits in a variety of biological active molecules and are 
useful intermediates in synthetic chemistry.12-14 A well-known approach for the synthesis of 
functionalised furans is transition metal-catalysed cyclisation of alkynyl,15,16 alkenyl,17 or 
allenyl ketones,18 alcohols or epoxides.19-21  
With respect to alkynyl ketones (28), Gevorgyan et al. investigated their utility as readily 
available starting materials for the synthesis of 2,5-disubstituted furans (29).22 The Cu(I)-
catalysed and base-assisted cycloisomerisation is believed to proceed via an intermediary 
allenyl isomer. This method yields disubstituted furans possessing different functional groups, 
such as alkenes, ethers, acetals, esters and alcohols (Scheme 1.7).  
O R1
R3X O R2
O
R4
O
R4
O
R1
R3 R2
Base
− HX
α-halocarbonyl β-dicarbonyl 3-furoate
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Scheme 1.7: Cu(I)-catalysed synthesis of  2,5-disubstituted furans. 
An extension of this methodology was further achieved by Gevorgyan et al. for the 
preparation of trisubstituted furans 32 and 33 by employing 4-thio and 4-acyloxybut-2-
ynones 30 and 31 in an innovative, Cu(I)-catalysed, synthetic route as illustrated in Scheme 
1.8.23,24 
Scheme 1.8: Synthesis of 3-thio- and 3-acyloxy-substituted furans. 1,2 migration has been 
proposed as the key step in the copper-catalysed propargyl-propenyl isomerisation in the 
synthesis of trisubstituted furans.25  
Since olefins are more readily available than are alkynes and allenes, Widenhoefer et al. 
exploited alkenyl substrates as suitable starting materials for the transition metal catalysed 
synthesis of furan via heterocyclization.26 In this scenario, α-alkenyl-β-diketone 34 
underwent furan formation using a Pd(II) source and CuCl2 as an oxidant to afford the 
trisubstituted furan 35 (Scheme 1.9).  
R1
R2
O R1 C
H
H
O
R2
CuI (5 mol%)
Et3N, DMA
100 oC
OR
1 R2
28 29
R1 = OTHP
R2 = tBu
O R
2R1
R3OCO
R1
R2
O
X
O R
2R1
R3S
CuI (5 mol%)
NEt3, DMA, 130 oC
CuCl (5 mol%)
NEt3, DMA, 130 oC
R1 C
H
X
O
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R1 O
R2
HO
O
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R1 O
R2
H
S
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30 X = SR3
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R1 = Me, R2 = Ph, R3 = Me R1 = (CH2)3OTHP, R2 = Me, R3 = Ph
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Scheme 1.9: Palladium-catalysed oxidative alkoxylation of an α-alkenyl-β-diketone to form 
a functionalised trisubstituted furan.25 
Synthesis of simple 3-substituted furans can be achieved via reductive annulation of 1,1,1-
trichloroethyl propargyl ethers employing catalytic Cr(II)Cl2 regenerated by Mn/TMSCl 
(Scheme 1.10).27 This reaction is synthetically useful in the synthesis of 3-substituted natural 
products. 
Scheme 1.10: Reductive annulation using catalytic Cr(II) regenerated from Mn/TMSCl 
The field of furan synthesis has attracted significant interest in the last century with the 
emergence of many natural and pharmaceutically important furan-containing substances.28 
The literature is saturated with concise methodology for accessing mono-, di-,tri-, or tetra-
substituted furans and will continue to rapidly advance with the discovery of more complex 
and challenging furan containing natural products. An extensive review by Kirsch et al. on 
recent developments in the synthesis of polysubstituted furans in available in the literature.25 
Ph nPent
O O
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1.1.6 Natural products containing the furan ring 
The furan ring system is found in many naturally occurring compounds, either as a fully 
unsaturated structure or in a reduced or partly reduced form. The majority of the naturally 
occurring compounds containing a fully unsaturated furan ring are terpenoid in character; 
like the di-substituted rosefuran 37 (rose oil) and mono-substituted perillene 36 (secondary 
plant metabolite). However, simple furan-containing natural products like furfuryl thiol 41 
(aroma in roasted coffee) do exist. Furans that occur in nature in a reduced or otherwise 
modified form include pentose sugars such as ribose 38 and deoxyribose 39, which are 
components of nucleic acids and several types of unsaturated γ-lactone like ascorbic acid 40 
(vitamin C) as seen in Figure 1.4.6,29 
 
 
 
Figure 1.4 
 
The furan ring is also present in a huge variety of natural products, such as polyketides, 
phenylpropanoids, alkaloids and terpenes. In general, the natural compounds containing the 
furan rings and its derivatives (di, tetrahydro, γ-lactone) have been found in all classes of 
terrestrial (fungi, bacteria, insects, plants) and marine (bacteria, fungi, algae, mollusc, sponge, 
seaweed) organisms.30 
The different structural types of natural products with furan rings cover the acetogenins 
(asimicin),31 morphinanes (morphine), cembranolides (deoxypukalide),32 manzamine-related 
alkaloid (nakadomarin),33 macrolide antibiotics, polycyclic ethers, lignans (podophyllotoxin), 
ginkgolides (ginkgolide B),34,35 quassinoids, limonoids, furanflavonides, furanoquinones, 
steroidal glycosides (cephalostatins,36 ritterazines37), macrodiolides (pamamycin),38 among 
others.30 Table 1.1 shows representative examples of the families of natural products 
containing furans. 
 
O
CH2OH OH
O
CH2OH OH
HOOHHO
O O
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H
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Table 1.1: Illustrates examples of the families of natural products containing furans* 
 
Bu
OH
3
OH
H
O O
H
OH
HH 9
O
O
Me
Asiminocin 42
O
O
O
O
H
O
HO
HO
O
OOH
tBu OH
O
O
O
O
Ginkgolide B 45
Cantharidin 43 O
HH
O
O
O
AcO
CO2Me
Salvinorin A 49
O
O
O
OH
O
OMe
OMe
MeO
Podophyllotoxin 48
O
O
O
O
O
O
O
NMe2
Pamamycin 44
(-)-Morphine 46
O
Pallescensin A 47
HO
HO
O
H N
H
H
Product Natural source Biological activity 
Asiminocin 42 Asimina triloba Antitumour, 
pesticidal, 
antimalarial39 
Cantharidin 43 Mylabris phalerata Hepatocarcinoma40 
Pamamycin 44 Streptomyces alboniger Antibiotic41 
Ginkgolide B 45 Ginkgo biloba Dementia and age 
related cognitive 
decline35,42 
Morphine 46 Daphniphyllum calycinum  Analgesic43 
Pallescensin A 47 Disidea pallescens Defence44 
Podophyllotoxin 48 Podophyllum Cytotoxic, antviral45 
Salvinorin A 49 Salvia divinorum Psychoactive46 
* Data sourced from ‘Heterocycles in Natural Product Synthesis’ by Boto et al.30  
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1.1.7 Isolation of furospongolide 
1.1.7.1 Introduction to furan derivatives isolated 
The transcription factor hypoxia-inducible factor-1 (HIF-1) has stimulated significant interest 
as a novel molecular target for anticancer drug discovery. Following its discovery by 
Goldberg and Semenza et al. in the early 90’s,47,48 numerous clinical trials strongly support 
HIF-1 as a valid molecular target for drug discovery in the treatment of tumour hypoxia.49,50 
Hypoxia influences many aspects of the biology of tumours and is directly associated with 
resistance to therapy, tumour progression, and patient mortality.51 Inhibition of HIF-1 
activation has been shown to suppress the growth and spread of hypoxic tumours.52 To the 
best of our knowledge, despite extensive drug discovery research, there is no approved drug 
that directly targets tumour hypoxia.53 The majority of small molecule HIF-1 inhibitors 
discovered and developed in recent times are indirect inhibitors of HIF-1 activation.54  
Marine natural products have recently become an extraordinary resource for the discovery of 
new anticancer agents that effectively suppress numerous antitumour molecular targets. 
Several research programs have begun to examine their potential as HIF-1 activation 
inhibitors.52,55,56 Thus far, cell-based and in-vitro high-throughput screening has been 
effective in identifying new compounds that inhibit HIF-1. At the forefront of these 
investigations has been Dale. G. Nagle. His research group extensively explored the 
biomedical potential of marine natural products as new sources of drug leads for the 
treatment of cancer, whereby the group developed new molecular-based bioassays to 
investigate natural products for their potential to supplement existing chemotherapeutic 
agents.  
Using a human breast carcinoma T47D cell-based reporter assay, Nagle et al. evaluated the 
HIF-1 inhibitory activity of over 15,000 natural product-rich extracts from various marine 
organisms and plants obtained from the NCI Open Repository. This screening effort has 
yielded an array of structurally diverse natural product-derived HIF-1 inhibitors such as 
manassantin B 50,57 7-hydroxyneolamellarin A 52,58,59 laurenditerpenol 51,60,61 and 
tetrahydroisoquinoline alkaloids klugine 53 and emetine 54 (Figure 1.5).62  
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Figure 1.5 
As part of this molecular-targeted antitumour drug discovery program, an active extract of 
the tropical marine sponge Lendenfeldia sp. (5 µg mL-1) collected from shallow water in 
Saipan was found to inhibit hypoxia (1% O2)-induced HIF-1 activation by 91%. Bioassay-
guided chromatographic separation of this active extract from the NCI Open Respository of 
marine invertebrate extracts yielded the terpene-derived furanolipid furospongolide 55, one 
novel scalarane sesterterpene 56 and two previously reported scalaranes 57 and 58 as 
illustrated in Figure 1.6.63-65 
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A photo of Lendenfeldia sp. which has been taken from the Wild Singapore website.66 
 
 
 
Figure 1.6: Illustration of the four components 55-58 isolated from an active extract of the 
marine sponge Lendenfeldia sp.  
 
The first reported isolation of furospongolide 55 was by Kashman et al. in 1980 from the 
marine sponge Dysidea herbacea collected in the Gulf of Suez (Red Sea).64 Following 
spectroscopic analysis of the C21 metabolite 55, data was consistent with the presence of a 
α,β-unsaturated-γ-lactone and a furan ring joined at the terminal ends of a linear carbon 
skeleton. The close relationship between 55 and the furospongin family led to the name, 
furospongolide 55.64,67  
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1.1.7.2 Biological evaluation of furospongolide  
The compounds 55-58 isolated from the active marine extract were tested independently in a 
concentration-response study to determine their effect on HIF-1 activation in T47D and PC-3 
(human prostate tumour) cell-based reporter assay (Figure 1.6).52 Among the four 
Lendenfeldia sp. metabolites isolated, furospongolide 55 was the only relatively non-
cytotoxic inhibitor of hypoxia (1% O2)-induced HIF-1 activation with an IC50 value of 2.9 
µM in the T47D breast tumour cell line (Figure 1.7). Disappointingly, the three scalaranes 
56-58 were found to be cytotoxic, showing only a narrow therapeutic window between the 
HIF-1 inhibitory activity and the suppression of cell proliferation/viability in T47D cells.  
 
 
Figure 1.7: Concentration response effect of furospongolide 55 on HIF-1 activity in T47D 
cell reporter assays as reported by Liu et al.52 “pHRE_Hyp”: cells were transfected with the 
pHRE-TK-Luc reporter; “pGL3Control_Hyp”: cells transfected with the control plasmid 
pGL3-Control; “pHRE_1,10-phen”: Cells treated with a hypoxia mimetic, 1,10-
phenanthroline (10 µM). 
 
Utilising cutting edge molecular mechanism-targeted bioassay techniques, furospongolide 55 
was found to suppress HIF-1 activation by inhibiting the hypoxia induction of HIF-1α 
protein. Furospongolide 55 was shown to block the hypoxia-induced production of the 
downstream HIF-1 target secreted Vascular Endothelial Growth Factor (VEGF) in a 
concentration dependant manner as illustrated in Figure 1.8. Surprisingly, furospongolide 55 
only weakly inhibited the induction of HIF-1α protein by 1,10-phenanthroline (chemical 
hypoxia). Thus, 55 selectively inhibits hypoxic activation of HIF-1 by blocking the induction 
of HIF-1α protein.  
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Figure 1.8: Furospongolide 55 inhibited hypoxia induction of HIF-1 target VEGF protein 
(A) and blocks the induction of nuclear HIF-1α protein accumulation (B) as reported by Liu 
et al.52 
 
The generation of mitochondrial reactive oxygen species (ROS) at complex III in hypoxic 
cells is generally believed to play a vital role in HIF-1 regulation. Mitochondria electron 
transport chain (ETC) inhibitors constitute one group of recently recognised small-molecule 
HIF-1 inhibitors.68,69 Inhibitors of the mitochondrial ETC could block the production of 
ROS-mediated signalling processes that stabilize HIF-1α protein under hypoxic conditions. 
Liu et al. used a Clark-type electrode system to measure mitochondrial respiration in the 
same T47D cells that were used to examine HIF-1 activation. Furospongolide 55 inhibited 
cellular oxygen consumption at concentrations as low as 10µM (38% inhibition) in a 
concentration dependant manner as illustrated in Figure 1.9.52 Additional mechanistic studies 
indicated that furospongolide 55 inhibits hypoxia-induced HIF-1 activity by blocking 
NADH-ubiquinone oxidoreductase (complex 1)-mediated mitochondrial electron transfer, 
thereby suppressing tumour cell respiration and hypoxic ROS generation.52  
55
Chapter 1  Introduction 
 
 20 
 
 
Figure 1.9: Furospongolide 55 inhibited oxygen consumption in T47D cells by disrupting the 
mitochondrial electron chain at complex I as reported by Liu et al.52 
 
Interestingly in 2013, Sagar et al. made a hypothesis linking furospongolide 55 to 
angiogenesis via the VEGF. Inhibition of VEGF has been shown in studies to block 
angiogenesis in tumour cells.70 Thus it was proposed by Sagar et al. that furospongolide 55 
could potentially be used as a drug to block angiogenesis in solid tumours (Figure 1.10).     
 
 
 
Figure 1.10: A basic summary of the possible mechanism of action of furospongolide 55 in a 
tumour cell as depicted by Sagar et al.70  
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While furospongolide 55 represents only a moderate potency inhibitor (IC50 2.9 µM), it is the 
first marine-derived furanolipid found to inhibit hypoxia-induced HIF-1 activation. The 
molecular target of 55 is linked with possible mitochondrial-associated toxicity and together 
with its arresting bioactivity and unusual natural structure, makes this furanolipid an 
attractive target for total synthesis, structural modification and possible pharmaceutical 
optimisation in the development of a potent anticancer agent.52,56  
 
1.1.8 Biological Background 
1.1.8.1 Cancer 
Cancer is a term used to describe diseases in which abnormal cells divide without control and 
are able to invade other tissues. There are more than 100 different types of cancer and they 
are classified by the organ or type of cell in which they start. All cancers begin in cells, the 
body's basic unit of life. When the genetic material (DNA) of a cell becomes damaged or 
changed, this results in mutations that affect normal cell growth and division. When this 
happens, cells do not die when they should, and new cells form when the body does not need 
them, effectively forming a mass of tissue called a tumour. Cells that invade nearby tissues 
and spread to other parts of the body are cancerous and the spread of cancer from one part of 
the body to another is called metastasis. 
A report from the National Cancer Registry of Ireland (NCRI) and the Central Statistics 
Office (CSO) shows the incidence, survival and mortality rates in Ireland from all cancers for 
men and women in 2013, the most recent reporting period available.71 According to the 
statistics, it is estimated that one in three people will develop cancer during their lifetime. 
Worryingly, an average of 30,000 new cases of cancer are diagnosed each year in Ireland and 
this number is expected to rise dramatically to over 40,000 per year by 2020. The five most 
common cancers in Ireland are non-melanoma skin cancer, prostate cancer, breast cancer, 
bowel cancer and lung cancer respectively. The average incidence of each of these cancers 
between 2009 and 2010 inclusive is illustrated below in Figure 1.11.   
Chapter 1  Introduction 
 
 22 
 
Figure 1.11: Illustration of the average incidence of the five most common cancers in 
Ireland between 2008 and 2010 inclusive. 
 
The most common type of cancer in Ireland is non-melanoma skin cancer across both 
genders. Excluding skin cancer however, breast cancer was the most common among women 
(2,767) while prostate cancer was the most common cancer among men (3,014) (Figure 
1.11). With respect to cancer mortality, cancer accounts for 25% of the annual death toll 
making it the second most common cause of death in Ireland. According to the most recent 
figures, 8,316 people died from cancer in 2010. Worldwide this figure was as high as 7.6 
million. Thankfully, with recent advances in medical research and the implementation of new 
treatment options for patients, cancer is viewed as a condition from which people survive. 
Statistically speaking, 42% of men and 50% of women diagnosed with cancer currently 
survive for five years and longer. Amazingly, it is estimated that 280,000 people, diagnosed 
between 1995-2009, have survived their cancer in Ireland. Cancer is still a major problem 
and it goes without saying that numerous laboratories around the world are investing huge 
time and energy into addressing this problem by continually developing new and more 
innovative treatment options for cancer patients.  
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1.1.8.2 Hypoxia 
Hypoxia is a common feature of most tumours that profoundly affects the biological 
behaviour, response to therapy and prognosis of human cancers.72,73 The presence of hypoxia 
in solid tumours has been recognised for more than 50 years.72 Hypoxia occurs when cells 
are located too far from a functional blood vessel for adequate supply of oxygen due to rapid 
cancer cell proliferation and the formation of blood vessels that are structurally and 
functionally abnormal. In the most extreme cases, oxygen supply is below that required for 
survival, resulting in cell death and the establishment of a selection of cancer cells in which 
the apoptotic pathways are inactivated and anti-apoptotic pathways are activated.51,74,75 These 
hypoxic cells are generally more resistant to killing by radiation and chemotherapy, are more 
invasive and metastatic, resistant to apoptosis, and genetically unstable.72,73 One of the major 
advances in cancer research over the last two decades has been the discovery of Hypoxia 
Inducible Factors (HIF), a family of transcription factors crucially involved in the response of 
mammalian cells to oxygen deprivation.48 The discovery of HIF-1 as a crucial player of the 
response to hypoxia has changed the perspective on how to target hypoxia for the 
development of cancer therapeutics by turning a strength of cancer cells into their Achilles’ 
heel.72 Clinical studies in cancer patients indicate that the expression of HIF-1 is directly 
correlated with poor patient prognosis and activation of HIF-1 contributes to advanced 
disease stages (malignant behaviour) and therapeutic resistance. Conversely, inhibition of 
HIF-1 activation has been shown to suppress growth, survival and metastatic spread of 
hypoxic tumours.52,56  
 
1.1.8.3 Hypoxia Inducible Factor (HIF) 
Since its discovery in 1992 by Semenza et al., HIF-1 has been the subject of thousands of 
published studies.50 It is widely accepted among experts that the Hypoxia Inducible Factor is 
the primary transcription factor activated by hypoxia and is responsible for orchestrating a 
number of cellular responses such as angiogenesis and glycolysis that are important to 
tumour cell survival under hypoxic conditions. Hypoxia-inducible factor-1 is a heterodimeric 
transcriptional factor consisting of a HIF-1α (120-kDa) and a HIF-1β subunit (80-kDa).53,76 
HIF-1 is a member of the rapidly growing Per-ARNT-Sim (PAS) family of basic helix-loop-
helix (bHLH) transcription factors which is activated during dimerisation of HIF-1α and HIF-
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1β (Figure 1.12).76 HIF-1α is a protein that in humans is encoded by the HIF-1α gene. HIF-
1α plays a major role in activating gene transcription, which is important for maintaining 
homeostasis under hypoxic conditions and is an obvious target for development of novel 
cancer therapeutics. 
 
 
Figure 1.12: Structure of the transcriptional factor HIF-1α. 
 
The level of HIF-1α protein is directly regulated by intracellular oxygen concentration. In the 
presence of oxygen (normoxic conditions) HIF-1α protein is rapidly degraded, while it is 
stabilized in the absence of oxygen (hypoxic conditions). HIF-1β protein on the other hand is 
always present (constitutively expressed). Upon hypoxic induction and activation, HIF-1α 
protein levels are dramatically increased and undergo heterodimerisation with HIF-1β protein. 
This activates HIF-1, which subsequently binds to the hypoxia response element (HRE) 
present in the promoters of target genes, which ultimately control angiogenesis, anaerobic 
metabolism, cell survival and metastasis as well as other cellular functions. 
 
More than seventy target genes that are activated by HIF-1 have been identified.77 These 
genes are involved in many aspects of cancer progression, angiogenesis, cell survival, 
glucose metabolism and invasion. These include genes encoding for vascular endothelial 
growth factor (VEGF), erythropoietin (EPO) and many numerous enzymes involved in 
glucose, iron and nucleotide metabolism. Hypoxia-inducible factor 1 (HIF-1) is therefore a 
master regulator of this adaptive response to hypoxia.78 Given the central role that HIF-1-
driven transcription factor activity has in compensating for loss of oxygen, it is clear that 
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modulation of that activity could be a potent mechanism for treating a wide range of 
hypoxia-related pathologies. A simplified representation of the processes influenced by HIF-
1 was provided by Quintero et al. and is exemplified in Figure 1.13. 
 
 
 
Figure 1.13 
 
With respect to HIF-α, three homologs have been identified: HIF-1α, HIF-2α and HIF-
3α.53,79 HIF-2α is closely related to HIF-1α and both are able to interact with hypoxia 
response elements, to up-regulate transcriptional activity. By contrast, HIF-3α is involved in 
down-regulation of the hypoxic response via an alternatively spliced transcription factor, 
which may function as an inhibitor of HIF-1α adding to the complexity in the regulation of 
hypoxia-inducible genes by the HIF family of transcription factors.80,81 
HIF-1α has two transactivation domains located in its COOH-terminal half, which are 
termed the NH2-terminal transactivation domain or N-TAD (amino acids 531-575) and the 
COOH-terminal transactivation domain or C-TAD (amino acids 786-826) as illustrated in 
Figure 1.14.82  
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Figure 1.14: Oxygen-dependant regulation of HIF-1α activity adapted from Xia et al. with 
some minor modifications.53,83  
 
The C-TAD of HIF-1α plays a key role in modulating the transcriptional activation of HIF-
1α under hypoxic conditions. On the other hand, N-TAD is involved in the stabilisation of 
HIF-1α under anoxic conditions. Under hypoxia, the C-TAD is able to interact with 
transcriptional co-activators like p300/CBP at N803. However under normoxic conditions, 
hydroxylation of N803 is mediated by an asparaginyl hydroxylase, known as factor inhibiting 
HIF-1 (FIH-1), which prevents HIF-1α from interacting with the transcriptional co-activator 
p300/CBP (Figure 1.14).84  
 
The von Hippel-Lindau protein (pVHL) is involved in the regulation of HIF-1α. Under 
normoxic conditions, oxygen-dependant hydroxylation of proline residues Pro402 and Pro564 
in HIF-1α by three prolyl-4-hydroxylase domain containing enzymes (PHD1-3) is required 
for binding of the von Hippel-Lindau tumour-suppressor protein, which is the recognition 
component of an E3 ubiquitin-protein ligase. VHL binding is also promoted by acetylation of 
K532 residue by the ARD1 acetyltransferase. This prolyl-hydroxylation ‘tags’ HIF-1α 
protein for polyubquitination mediated by the pVHL E3 ubiquitin ligase complex, followed 
by rapid degradation through a 26S proteasome-dependent mechanism (Figure 1.14).85  
bHLHHIF-1α PAS N-TAD
K532 P564 N803
C-TAD
p300/CBP
Transcriptional 
activation
FIH-1
OHOH
P402
OH
CH3-C=O
VHLPolyubiquitination
Degradation
Normoxia
Hypoxia
PHD1-3ARD1PHD1-3
Chapter 1  Introduction 
 
 27 
Under hypoxic conditions, the rate of N803 and K532 hydroxylation decreases dramatically 
and VHL protein can no longer bind to HIF-1α that is not prolyl-hydroxylated, resulting in a 
decreased rate of HIF-1 degradation. As previously stated, p300/CBP can now bind to HIF-
1α that is not asparaginyl-hydroxylated, resulting in transcriptional activation of HIF-1 target 
genes (Figure 1.14).53,83  
 
1.1.8.4 Hypoxia-induced mitochondrial reactive oxygen species 
Natural product-based small molecule inhibitors of the mitochondrial electron transport chain 
(ETC) have been found to inhibit hypoxia-induced HIF-1 activation.68,69,86-88 The mechanism 
is not fully understood, but several opposing theories have emerged to explain the role of 
mitochondria in the regulation of HIF-1 activation.89,90 Under hypoxic conditions, reactive 
oxygen species (ROS) such as superoxide anion and hydrogen peroxide are produced by the 
Qp site of mitochondrial complex III (Figure 1.15). These hypoxia-induced ROS are 
believed to function as signalling molecules that oxidise the catalytic Fe(II) in Fe(II)-
dependent HIF-prolyl hydroxylase that is essential in the initial steps of ubiquitin-mediated 
proteasomal degradation of HIF-1α protein.68,86,87,91,92 Furthermore, mitochondrial ROS have 
also been linked to the inhibition of the Fe(II)-dependent asparaginyl hydroxylase [factor 
inhibiting HIF, (FIH)] which interferes with HIF-1 transcriptional activation by 
hydroxylating the N803 asparagine in the C-TAD of  HIF-1α (Figure 1.14).  
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Figure 1.15: The mitochondria of hypoxic cells release superoxide from the Qp site of 
mitochondria complex III. This prevents the transfer of electrons required to drive the 
hypoxia-induced production of reactive oxygen species at complex III. The marine natural 
product furospongolide 55 inhibits the mitochondrial electron transport chain at the NADH-
ubiquinone oxidoreductase (complex I) site.56  
 
As previously stated in Section 1.1.7.2, it has been postulated that the mechanism through 
which furospongolide 55 inhibits hypoxia-induced HIF-1 activity is linked to inhibition of 
the mitochondrial ETC by suppressing the production of ROS signalling pathways in hypoxic 
tumours. This stabilises HIF-1α protein by preventing proteasomal degradation under 
hypoxic conditions and activates HIF-1 by interfering with the ability of asparaginyl 
hydroxylase to suppress HIF-1 activation.  
 
 
 
 
 
Furospongolide
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1.1.8.5 Small molecule HIF-1 inhibitors and chemoprevention 
In brief, the progression of cancer is correlated with the development of hypoxic regions 
within solid tumours. HIF-1 is a transcriptional factor activated by hypoxia, which 
orchestrates the expressions of specific genes associated with conferring radio- and chemo 
resistance while simultaneously inducing angiogenesis, enhancing tumour development and 
promoting metastasis. As a result, HIF-1 has emerged as a key molecular target for 
anticancer drug discovery.56 Over the last decade intense efforts has been made to investigate 
natural products that can be potentially used as HIF-1 inhibitors. In general, natural products 
have been a major source of new drugs for centuries and statistics show that nearly 50% of 
approved anticancer agents are derived directly or indirectly from natural products.93 The 
importance of natural products in drug discovery has been discussed in several reviews and 
reports.94-97  
 
As our knowledge of the tumour cell continues to expand, stronger evidence suggests that 
inhibition of the HIF-1 pathway represents an attractive approach to cancer therapy. Recently, 
numerous laboratories have joined in the race to discover small molecule HIF-1 
inhibitors,72,98,99 most of which use a synthetic or commercial compound library-based 
screening approach. Small molecules aim to suppress tumour hypoxia and to increase the 
susceptibility of tumour cells to radiotherapy and chemotherapy thereby improving patient 
outcome. They also serve as important molecular probes to investigate the pathways that 
regulate HIF-1 activity. Xia et al. disclosed a review on recent advances in discovery and 
development of small molecule HIF-1 inhibitors.53 Representative HIF-1 inhibitors 
discovered from compound library screening efforts include topotecan,100 echinomycin,101 
chetomin,102 a benzopyran derivative 103D5R, analogues of emetine and actinomycin D,103 a 
pyrroloquinoline derivative DJ12,104 and a group of structurally diverse compounds including 
alkyliminophenylacetates that affect mitochondrial function.105 For many of these, the 
mechanism of action has been established and involves a reduction of HIF-1α mRNA or 
protein levels, HIF-1 DNA-binding activity, or HIF-1 mediated transactivation of target 
genes (Table 1.2).74  
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Table 1.2: Anticancer agents that inhibit HIF-1 activity* 
Mechanism of action Drug molecule 
Decrease HIF-1α mRNA levels GL331106 
Decrease HIF-1α protein levels Ibuprofen, Celecoxib107 
Topoisomerases Topotecan100 
Cyclin-dependent kinases Flavopiridol108 
Microtubule targeting agents 2-Methoxyestradiol109 
Decreased binding of HIF-1 to DNA Echinomycin,101 DJ12104 
Decreased HIF-1 mediated transactivation Bortezomib,110 Chetomin102 
Inhibits mitochondrial ETC Laurenditerpenol,60 Furospongolide52 
Unknown Manassantins,57 103D5R111 
* Information was sourced from a review by Semenza et al.74 
 
Unfortunately, many of the identified compounds have poor water solubility and are very 
toxic and therefore cannot be used in human therapy. Using a natural product chemistry-
based approach, several groups have discovered chemically and mechanistically diverse HIF-
1 inhibitors. Some of these HIF-1 inhibitors function at low nanomolar concentrations (e.g. 
manassantins) with a wide therapeutic window between their HIF-1 inhibitory activity and 
cytotoxicity.56,57 A number of fantastic reviews have been published discussing natural 
compounds with HIF-1 inhibitory activity that have been discovered to date.112-114  
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1.1.8.6 HIF-1 inhibitors from marine life 
The potential of marine life as a source of novel molecules for the treatment of human 
diseases is extraordinary. Recent technological and methodological advances in structure 
elucidation, organic synthesis and biological assay has resulted in the isolation and clinical 
evaluation of various novel anticancer agents from marine organisms.115,116 Natural products, 
especially those from terrestrial plants and microbes, have long been a traditional source of 
drug molecules (morphine and penicillin). Modern pharmaceutical discovery programmes are 
indebted to natural products as active compounds from plants and microbes represent an 
invaluable pipeline for new investigational drugs.117,118 On the other hand, marine organisms 
possess a greater molecular diversity than their terrestrial counterparts due to their longer 
evolutionary history. Recent research has discovered that marine life produce more antibiotic, 
anticancer and anti-inflammatory substances than any group of organisms on land.119 The 
major problem with developing drugs from a marine source is that procurement or 
manufacture of quantities of rare compounds to ensure a sustainable supply to industry was 
essentially a bottleneck. Sponges and their microbial fauna are largely unculturable, and the 
valuable compounds they produce must be extracted and purified from specimens collected 
by hand from shallow to deep waters. Nevertheless, the unrivalled potential of marine natural 
products as antitumour agents has inspired innovative solutions to the supply problem 
ranging from aquaculture to total synthesis.120  
 
The past two decades has seen a dramatic increase in the number of preclinical anticancer 
lead compounds from diverse marine life enter human clinical trials (Figure 1.16). 
Ziconotide 59 (Prialt®, Elan Pharmaceuticals), a peptide originally discovered in a tropical 
cone snail (Conus magus) was the first marine-derived compound to be approved in the US 
in December 2004 for the treatment of pain (non opioid and non NSAID analgesic).121,122 In 
October 2007, trabectedin 60 (Yondelis®, PharmaMar) became the first marine anticancer 
drug to be approved in the EU.123 Currently, the antitumour agent plitidepsin 61 (Aplidin®, 
PharmaMar) is in phase III clinical trials for the treatment of multiple myeloma.124,125  
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Figure 1.16: Marine derived pharmaceutical drugs. 
 
Numerous other marine natural products, primarily invertebrates (e.g., sponges, tunicates, 
bryozoans, and mollusks) have shown potent antimitotic and/or antitumour properties and 
have advanced to late-stage clinical trials.123,126 The literature has many comprehensive 
reviews discussing the importance of marine natural products in anticancer drug 
discovery.115,116,119,127 With respect to Aplidin® 61, links have been made which suggest it 
functions as an inhibitor of HIF-1 activation by suppressing the expression of HIF and 
angiogenesis-related HIF-1 target genes in vivo.128,129  
 
Several research programs have recently begun to examine marine natural products as a 
potential source of HIF-1 activation inhibitors.56,112 The first marine natural product found to 
inhibit hypoxia-induced HIF-1 activation was laurenditerpenol 51, a diterpene first isolated in 
2004 from the marine red algae Laurencia intricate (Table 1.3, Entry 1).60 Interestingly, 
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despite having little to no structural homology, both laurenditerpenol 51 and furospongolide 
55 inhibit hypoxia-induced HIF-1 activation in breast cancer cells by inhibiting NADH-
ubiquinone oxidoreductase-mediated mitochondrial signalling pathways.52,56,60 Bioassay-
guided isolation has since yielded an array of HIF-1 inhibitors from sponges and other 
marine organisms. Two good examples include the macrolide macrolide latrunculin A 62, 
isolated from a Red Sea sponge Negombata magnifica,130 which is now commercially 
available from Sigma Aldrich,131 and the phenolic pyrrole alkaloid 7-hydroxyneolamellarin 
A 52 isolated from the sponge Dendrilla nigra (Table 1.3, Entry 2 and 3).58 Within our 
research group, studies are currently in progress towards the synthesis and biological 
evaluation of novel neolamellarin analogues as potential antitumour agents.132 To date, the 
most potent marine natural product inhibitor of hypoxia induced HIF-1 activation is 
mycothiazole 63, a polyketide isolated in 2002 from the marine sponge Cacospongia 
mycofifiensis (Table 1.3, Entry 4).133,134 As illustrated in Table 1.3, these marine natural 
products vary widely in potency and selectivity to target HIF-1 and ultimately tumour 
hypoxia.  
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Table 1.3: Marine natural products found to inhibit hypoxia-induced HIF-1 activation in 
T47D human breast cancer cells*.  
 
 
Entry Product Natural source IC50 value 
1 Laurenditerpenol 51 Laurencia intricata 0.4 µM 
2 7-Hydroxyneolamellarin 52 Dendrilla nigra 1.9 µM 
3 Latrunculin A 62 Negombata magnifica 6.7 µM 
4 Mycothiazole 63 Cacospongia mycofijiensis 1 nM 
* Data sourced from a review on marine natural products as HIF-1 inhibitors by Nagle et al. 56 
 
One of the intended applications of natural product-based HIF-1 inhibitors is as adjunct 
agents to be used in combination with other cancer treatment options.56 Preclinical studies 
strongly support this treatment regime of combining HIF-1 inhibition with radiation and 
chemotherapy to improve patient outcome.56,135,136 As the exploration for HIF-1 targeted 
antitumour natural products continues to expose innovative lead compounds, a greater 
prospect of identifying a potent clinically useful inhibitor of HIF-1 activation is at hand. 
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1.1.9 Sesterterpenoids 
1.1.9.1 Introduction to sesterterpenoids 
Terpenes are an enormous class of natural products spanning well over 30,000 members. 
They have been used throughout history for a broad variety of purposes including perfumes, 
medicine and flavouring.137 Terpenoids are derived from C5 isoprene units joined in a head 
to-tail fashion. Typical structures contain carbon skeletons represented by (C5)n, and are 
classified as hemiterpenes (C5), monoterpenes (C10), sesquiterpenes (C15), diterpenes (C20), 
sesterterpenes (C25), triterpenes (C30) and tetraterpenes (C40) as illustrated in Scheme 1.11.137 
 
 
 
Scheme 1.11 
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The two biosynthetic pathways leading to terpenoids are the mevalonate pathway and the 
more recently discovered mevalonate-independent deoxyxylulose pathway for the production 
of isopentyl diphosphate (IPP) and dimethyl allyl diphosphate (DMAPP), which are the 
biochemically active isoprene units (Scheme 1.12).137  
 
 
 
Scheme 1.12: The chemistry of the mevalonate and deoxyxylulose pathway as by Dewick et 
al.137 
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Within the terpenoid family, sesterterpenoids probably form the smallest class, comprising 
less than a thousand known compounds.137,138 They comprise of two and a half (sester in 
latin) terpene units, which for historic reasons were defined as pieces made of ten carbons. 
As such, sesterterpenoids contain 25 (or slightly fewer) carbon atoms. Their sources are 
widespread, having been isolated from terrestrial fungi, lichens, higher plants, insects and 
various marine organisms especially sponges.138    
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 1.13 
 
Sesterterpenoids are a group of pentaprenyl substances formed from combination of 
geranylgeranyl diphosphate (GGPP) and IPP via the enzyme prenyl transferase, which yields 
geranylfarnesyl diphosphate (GFPP). This is believed to involve ionisation of GGPP to the 
allylic cation, addition to the double bond of IPP, followed by loss of a proton. This produces 
a sesterterpene diphosphate, geranylfarnesyl PP, in which the new double bond is trans (E) 
(Scheme 1.13). 
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1.1.9.2 Synthetic approaches towards sesterterpenoids 
Terpenoids have played a important role in developing organic synthesis as far back as 
Komppa’s pioneering work on camphor in the early 1900’s.139,140 Many important concepts 
in organic chemistry such as Wagner-Meerwein rearrangements, Diels-Alder reactions, or 
polyolefin cyclization, were first explored with members of this large natural product class. 
With huge advancements in organic synthesis in recent years, complex terpenoids have been 
targeted and their total syntheses must now number in the hundreds.141  
Sesterterpenoids represent an attractive target for both biomedical and synthetic 
purposes,142,143 as this structurally complex terpenoid family exhibit diverse biological 
activity such as anti-inflammatory,144 cytotoxic, anticancer,145 antimicrobial,146,147 
antitubercular,148,149 and anti-biofilm activities.150 They exhibit inhibitory activity against 
parasitic protozoa,151 suppression of the expression of cyclooxygenase-2 and inducible nitric 
oxide synthase,152 and act as inhibitors of hypoxia-inducible factor-1 (HIF-1).112 The natural 
products of the sesterterpenoid subclass possess a linear carbon chain, which in most cases 
has been partially oxidized leading to cyclization at the terminal ends of the terpenoid chain 
resulting in furans and/or lactones. Although numerous linear sesterterpenoids have been 
reported,138,153,154 very few have been targeted by synthetic chemists to date.141 
In this short section, I will be reviewing efforts undertaken towards the synthesis of linear 
and bicarbocyclic sesterterpenoids, focusing on completed total syntheses of marine natural 
products, which have shown promising biological activity towards the treatment of human 
related diseases.  
A number of reviews have been published by Hanson et al. and Liu et al., which extensively 
cover the isolation, structure and biological evaluation of sesterterpenoid marine natural 
products from 1970 to 2013.138,153,155-157  
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1.1.9.2.1 Synthesis of furospinosulin-1 
Marine organisms, particularly sponges, have continued to provide a source of linear 
sesterterpenoids.157 The terminal units often comprise either of a furan, a γ-lactone or a 
tetronic acid moiety. Furospinosulin-1 69 was first isolated in 1972 from the marine sponge 
Ircinia spinosula by Cimino et al. and has very recently shown promising activity as a 
hypoxia-selective growth inhibitor following its isolation from an Indonesian marine sponge 
Dactylospongia elegans.158,159 Furospinosulin-1 69 showed selective antiproliferative activity 
against DU145 human prostate cancer cells under hypoxic conditions and exhibited 
antitumour activity at a level of 10-50 mg kg-1 after oral administration to a mouse model 
inoculated with sarcoma S180 cells. Mechanistic analysis revealed that 69 suppressed the 
transcription of the insulin-like growth factor-2 gene (IGF-2), which is selectively induced 
under hypoxic conditions through presentation of the binding of nuclear protein to the Sp1 
consensus sequence in the IGF-2 promoter region.158 These intriguing bioactivities prompted 
Kotoku et al. to develop a concise total synthesis of furospinosulin-1 69 and further 
investigate its structural-activity relationship (Scheme 1.14).160  
  
 
 
Scheme 1.14 
 
The first geometry-selective total synthesis of furospinosulin-1 69 is illustrated in Scheme 
1.14. The route-defining step involved a sulfone-mediated cross coupling reaction between 
allylic bromide 67 and the known farnesyl phenylsulfone 68. The allylic bromide 67 was 
conveniently prepared from commercially available 3-bromofuran 64. The first step involved 
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reacting trimethyleneoxide with the derived organolithium species of 3-bromofuran 64 to 
afforded 3-substituted furan alcohol 65. Oxidation and subsequent Wittig olefination 
provided the enoate 66. Diisobutylaluminium hydride reduction of the ester moiety in 66 and 
subsequent bromination with CBr4/PPh3 under standard Appel conditions furnished the 
allylic bromide 67. The coupling reaction between the allylic bromide 67 and the sulfone 68 
proceeded smoothly using potassium tert-butoxide. Subsequent reductive desulfonylation 
using Super-Hydride® lithium triethylborohydride in the presence of Pd(dppp)Cl2 
successfully furnished furospinosulin-1 69 in seven linear steps from 64. Since 
furospinosulin-1 69 is structurally similar to furospongolide 55, quite a number of synthetic 
transformations discussed here can be utilised in the synthesis of our target molecule 55 
especially methodology for attaching the furan moiety to the lipophilic terpenoid sidechain.  
 
Living organisms produce sesterterpenoids for certain physiological functions. Given the 
different selection pressures under which organisms have evolved over time, an enormous 
number of structural diversity is expected. With regard to furospinosulin-1 69, both the 
butenolide derivative 71 and the thiophene derivative 70 have been isolated from marine 
origin and have shown interesting bioactivity (Figure 1.17).161,162 
 
 
 
 
 
Figure 1.17 
 
The butenolide 71 was first isolated from the Caribbean sponge, Thorecta horridus and has 
been found to possess marked inflammatory activity inducing the release of histamine and 
cause oedema in the paw of test animals.157,161 On the other hand, the thiophene sesterterpene 
70 has recently been isolated from an active extract from the Sikao Bay sponge Xestospongia 
sp.162 Surprisingly, this was the first reported discovery and isolation of a thiophene 
containing sesterterpene produced by a marine sponge. Worth mentioning, sulfur is often 
found in marine natural products in the form of the isothiocyanate, thiocyanate, thioacetate, 
O 3OS 3
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thiol, sulfone and sulphate functional groups, whereas the thiazole is a common natural 
heterocyclic moiety.162 Furthermore, sesterterpenoid 70, which is almost identical in structure 
to furospinosulin-1 69 was found to be cytotoxic against Vero cells.162   
 
With regard to the length of the acyclic terpenoid chain, two structural derivatives of 
furospinosulin-1 69 have been isolated from the marine sponge Ircinia spinosula, 
difurospinosulin 75 and furospinosulin-3 73 (Figure 1.18).159 Interestingly, it has been 
suggested by Cimino et al. that difurospinosulin 75 could be derived from the C35 linear 
furanoterpene, furospinosulin-3 73 by the loss of four carbon atoms following biological 
inter-conversions involving enzyme catalysed oxidation, reduction and proton initiated 
cyclisation. Similarly, it has been proposed that anhydrofurospongin-1 74 can be derived 
from the C25 linear furanoterpene, furospinosulin-1 72 through an identical metabolic 
pathway. Further enzyme catalysed oxidation would potentially afford furospongolide 55. 
 
 
 
Figure 1.18 
 
When furospongolide 55 was isolated back in 1980 by Kashman et al. from the marine 
sponge Dysidea herbacea, furanoterpenes that terminated in a lactone ring were completely 
unknown in the C21-furanoterpene series but not unfamiliar in other marine metabolites.64,163 
In the last 3 decades, very few novel sesterterpenoids encompassing both a furan and lactone 
ring have been isolated from marine life. One obvious example is the C22 lactone 77, which is 
associated with furospongolide 55 both in structure and origin as it was isolated from the 
same species of Madagascan sponges of the genus Lendenfeldia (Figure 1.19).164  
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Figure 1.19 
 
Dehydrofurodendin 77 contains a β,γ-unsaturated-δ-lactone ring which is extremely rare 
among marine metabolites and in fact only exists in dehydrofurodendin 77, furodendin  76 
and in another C21 terpenoid. The C22 lactone, furodendin 76, has been reported in the sponge 
phyllosponngia dendyi.165 It should be noted that dehydrofurodendin 77 differs from 
furodendin 76 only in the additional double bond at C14-C15, which probably results from 
oxidation occurring at a late stage in the biosynthesis. Interestingly, dehydrofurodendin 77 
has been found to be a potent inhibitor of HIV-1 RT-associated DNA polymerase activity. It 
is important to highlight here how making simple changes to the structure of the molecule 
can affect its bioactivity and alter its therapeutic potential.   
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1.1.9.2.2 Synthesis of variabilin 
As previously stated, the terminal units of linear sesterterpenoids often comprise of a furan, 
lactone or a tetronic acid moiety. These natural products presumably occur following partial 
oxidation of the linear chain followed by cyclisation. Quite a number of the sesterterpenoid 
family contain a tetronic acid moiety and show strong antibiotic activity against 
staphylococcus aureus.155 Common examples are variabilin 78 from Ircinia variabilis,166 its 
double bond isomer strobilinin 79 from Ircinia strobilina,167 and fasciculatin 80 from Ircinia 
fasciculate (Figure 1.20)168 
 
 
 
Figure 1.20 
 
Variabilin 78 was first isolated by Flaukner et al. in 1973 from the marine sponge Ircinia 
variabilis (I. variabilis).169 A variety of geometric, stereo- and regioisomers of this natural 
product and other related types have since been isolated and have shown to possess 
remarkable antiviral and cytotoxic activity.170-173 Variabilin 78 is recognised as a novel RGD-
containing antagonist of glycoprotein IIb-IIIa and a platelet aggregation inhibitor.174 It is also 
a dual inhibitor of human secretory and cytosolic phospholipase A2 (PLA2) with anti-
inflammatory activity.172  
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More than 30 years after its isolation, the naturally occurring linear furansesterterpene 
tetronic acid, (18S)-variabilin 78 was first synthesised by Yoda et al.171  
 
 
 
Scheme 1.15 
 
The synthetic route began with the lipase PS-catalysed asymmetric desymmetrization of the 
1,3-propanediol 81 to furnish the mono acetate 82 in both high chemical and enantiomeric 
excesses (98% ee) respectively, to install the sole stereocenter (Scheme 1.15). The mono-
acetate 82 was converted into the silyl ether 83 through a three-step sequence and was 
subsequently coupled with the furanyl side chain 84 leading to the silyl sulfone 85 (Scheme 
1.16).  
 
 
Scheme 1.16: Total synthesis of variabilin 78 by Yoda et al.171 
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Oddly, the synthesis of the furanyl side chain 84 was not fully disclosed in the report by 
Takabe et al. It is presumed that 84 was prepared by furanylation of allylic sulfone 89 with 3-
furylmethyl bromide 90 through an sp3-sp3 cross coupling reaction to afford dendrolasin 91 
followed sequentially by allylic oxidation and chlorination chemistry (Scheme 1.17). 
 
 
 
Scheme 1.17: Preparation of the furanyl side chain 84. 
 
Compound 85 was then subjected to desulfonylation and deprotection chemistry to furnish 86, 
the chiral segment of variabilin 78 (Scheme 1.16). In order to introduce the conjugated 
tetronic acid moiety, a coupling reaction of 86 after TPAP-induced oxidation to an aldehyde 
intermediate was effected with methyl tetronate 87 in the presence of LDA. Finally, 
dehydroxylation under basic conditions and demethylation of 88 completed the first 
asymmetric synthesis of variabilin 78 (Scheme 1.16).  
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1.1.9.2.3 Synthesis of palinurin 
Similar to variabilin 78, the first reported isolation of (+)-palinurin 103 was from the 
Mediterranean marine sponge Ircinia variabilis.175 Palinurin 103 has emerged as a non-ATP 
competitive glycogen synthase kinase 3β (GSK-3β) inhibitor, a kinase implicated in 
Alzheimer’s disease.176-178 Recently, Gomez et al. accomplished the first enantioselective 
synthesis of (+)-palinurin 103 starting from commercially available furaldehyde 92 and (R)-
Roche ester 99.179 The key step in the synthesis was a Horner-Wadsworth-Emmons reaction 
to construct the alkene unit by coupling the phosphine oxide 95 and the tetronic moiety 102 
(Scheme 1.18). 
 
 
Scheme 1.18: Total synthesis of palinurin 103 by Gomez et al.179 
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Preparation of the phosphine oxide 95 involved 9 linear steps from furaldehyde 92 (Scheme 
1.18). The 3-substituted furan alcohol 93 was prepared by a Wittig reaction of 92 followed 
sequentially by reduction and catalytic hydrogenation. The alcohol 92 was converted to its 
corresponding iodide and then nitrile before reacting it with methyllithium to afford a ketone 
substrate, which was subjected to a Horner-Wadsworth-Emmons reaction to obtain the α,β-
unsaturated ester 94. Reduction of 94 with DIBAL-H gave the corresponding allylic alcohol, 
which was finally converted into phosphine oxide 95.   
Preparation of the requisite tetronic moiety 102 began with reacting methyl tetronic acid 96 
with pyrrolidine 97 under Dean-Stark conditions to afford the chiral enamino-furanone 98. 
Cross coupling of 98 with the allylic bromide 100 under the influence of the chiral tether 
provided the chiral furanone 101. Removal of the silyl protecting group using TBAF and the 
chiral auxiliary with aqueous hydrochloric acid gave the corresponding alcohol, which was 
subsequently reacted with methanol under Mitsunobu conditions followed by Swern 
oxidation to afford the target aldehyde 102.  
With respect to the Wittig-Horner reaction, treatment of phosphine oxide 95 with n-
butyllithium generated its corresponding anion, which was subsequently coupled with the 
aldehyde 102. Finally, demethylation concluded the first enantioselective total synthesis of 
palinurin 103 (Scheme 1.18).  
 
1.1.9.2.4 Synthesis of (-)-ircinianin and (+)-wistarin 
Two bicarbocyclic sesterterpenoids marine natural products, (-)-ircinianin 104 and its cyclic 
isomer (+)-wistarin 105 have been the subject of numerous synthetic studies.180-182 (-)-
Ircinianin 104 was isolated in 1977 by Hofheinz et al. from the marine sponge, genus 
Ircinia,183 while (+)-wistarin 105 was isolated from the marine sponge, Ircinia wistarii,184 by 
Gregson et al. in 1982. Despite the additional complexity in structure, both 104 and 105 are 
members of the same family of furanosesterterpenetetonic acids as variabilin 78 and 
palinurin 103. As expected, much of the same methodology previously described for 78 and 
103 was utilised in the synthesis of 104 and 105. The first total synthesis of ircinianin 104 
was achieved in 1986 by Takeda et al. inspired by a biogenetic hypothesis proposed by 
Hofheinz et al. on the construction of the spirotetronic ring by intramolecular Diels-Alder 
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(IMDA) cyclisation.183 Uenishi et al. revised this route almost eleven years later, completing 
an enantioselective synthesis of (-)-ircinianin 104 in 1997 as illustrated in Scheme 1.19. 
Scheme 1.19: Total synthesis of (-)-ircinianin 104 and (+)-wistarin 105 by Uenishi et al.182 
Biogenetically, it was assumed that (-)-ircinianin 104 was formed enzymatically or thermally 
by intramolecular Diels-Alder reaction from an acyclic tetronic acid precursor similar in 
structure to 108 in nature.182 The key step therefore in the synthesis of 104 involved a NiCl2-
CrCl2 mediated coupling reaction of aldehyde 106 and conjugated triene 107. The synthesis 
of the chiral aldehyde 106 began from (R)-Roche ester 99 (Scheme 1.19) with preparation of 
the γ-methylene-butenolide substructure in a similar fashion to that shown previously for 
variabilin 78 (Scheme 1.16). Likewise, synthesis of the conjugate triene 107 was achieved 
using a similar pathway previously described for palinurin 103 (Scheme 1.18). 
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The Nozaki-Hiyama-Kishi (NHK) reaction of 106 and 107, followed by an intramolecular 
Diels-Alder reaction furnished the tricyclic adduct 110. Interestingly, Ueniski el al observed 
that isomer 108 obtained from the NHK reaction was spontaneously cyclised to 110, whereas 
the isomer 109 remained unreacted under the same conditions and could easily be isolated 
from the reaction mixture. Finally, Barton deoxygenation and demethylation led to (-)-
ircinianin 104 (Scheme 1.19). Moreover, intramolecular iodo-etheration for the formation of 
a tetrahydropyran ring followed by radical-induced reductive deiodination accomplished the 
total synthesis of (+)-wistarin 105 (Scheme 1.19). It is worth noting that wistarin 105 was the 
first example of a sesterterpenoid that occurs naturally in both enantiomeric forms.185  
1.1.9.2.5 Synthesis of ircinin-4 
The 2,4-disubstituted furan motif is present in various physiologically active natural products 
such as 111-114 isolated from marine sources. Ircinin-4 111 is a member of a large family of 
furanoterpenes, some of which are illustrated in Figure 1.21 and deserve mentioning due to 
issues related to their biosynthesis,186 and more importantly, because of the interesting 
biological effects exerted by these compounds.187-189 
Figure 1.21: 2,4-Disubtituted furanosesterterpenoid marine natural products. 
O O
COOH
O O
O
O
OH
O O
O
OH
OIrcinin-4 111
Ircinin-1 112
Dehydrospongionellin 114
O O O
COOH
Hippospongin A 113
Chapter 1 Introduction 
50 
The first total synthesis of ircinin-4 111 was achieved by Frustner et al. in 1999,188 almost 
two decades after its isolation from the Mediterranean marine sponge Ircinia oros by Cimino 
et al.190 Synthesis of ircicin-4 111 began with the preparation of segment 119. Reaction of 3-
furylacetaldehyde 115 with the sulfur ylide of 116 formed by deprotonation with tert-
butyllithium gave the epoxide 117 (Scheme 1.20). The functionalised sulfonium salt 116 was 
a valuable building block frequently used within Furstner’s research group especially in the 
concise synthesis of the antitumour alkaloid roseophilin.191,192  
Scheme 1.20: The first total synthesis of the marine natural product ircinin-4 111. 
Synthesis of the allylic alcohol 118 was innovatively accomplished via a palladium catalysed 
ring opening of the vinyloxirane 117 employing Pd(PPh3)4. The mechanism involved 
deprotonation of bis(phenylsulfonyl)methane by the alkoxide unit of the π-allylpalladium 
complex resulting in regioselective attack at the electrophilic organopalladium species to 
furnish 118. Transformation of 118 into the desired furanylmethylfuran 119 was achieved by 
temporary protection of 118 as a THP acetal followed by desilylation and selective oxidation. 
Subsequent treatment of the resulting aldehyde with aqueous hydrochloric acid cleanly 
furnished the furanylmethylfuran 119 (Scheme 1.20).  
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Segment 122 was prepared in 4 linear steps from commercially available citronellol 120 
(Scheme 1.20). The two initial steps involved O-silylation and oxidation using ozone to 
furnish the aldehyde 121. A modified Wittig reaction delivered the (Z)-configurated allyl 
alcohol as a single isomer.193-195 The final step in the synthesis of the allylic bromide 122 
involved a bromination reaction using NBS.  
Reductive metalation of bis-sulfone 119 with lithium naphthalenide followed by addition of 
the allylic bromide 122 provided the desired coupling product 123. Desulfonylation and 
deprotection chemistry gave the corresponding primary alcohol. Due to the inherent labile 
nature of the furan to oxidation, transformation to ircinin-4 111 was successfully achieved 
employing a carefully controlled two-step protocol using PDC and silver nitrate (Scheme 
1.20). 
1.1.9.2.6 Synthesis of (+)-manoalide and related monocarbocyclic derivatives 
Monocarbocyclic sesterterpenoids are an important series of marine sponge metabolites 
belonging to the sesterterpene class. (+)-Manoalide 124 is the parent compound in this series 
and was first isolated in 1980 by Scheuer et al. from a Pacific sponge Luffariella variablis.196 
One year later, Scheuer et al. reported three additional related metabolites from the same 
Pacific sponge, namely secomanoalide 125, (E)-neomanoalide 126 and (Z)-neomanoalide 
127. All three compounds, as well as the parent compound, displayed antibacterial activity 
against Gram-positive bacteria (Staphylococcus aureus and Bacillus subtilis) (Figure 1.22). 
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Figure 1.22 
Since its discovery, (+)-manoalide 124 has attracted considerable attention from synthetic 
organic chemists with the first reported racemic synthesis in 1985 by Katsumara et al.,197 
which was followed by six additional syntheses of the racemate by the groups of Garst,198 
Katsamura,199 Kocienski,200 and Hoffmann.201 The structure of manoalide 124 is relatively 
simple as it only embodies one defined stereogenic center. The interesting fact about 
manoalide 124 is its biological profile, showing fantastic activity as a potent and irreversible 
inhibitor of phospholipase A2, which is the enzyme that catalyses arachidonic acid release in 
the formation of pro-inflammatory factors.202,203 Despite the number of syntheses available, 
only two enantioselective routes towards (+)-manoalide 124 have been reported in the 
literature. 204,205   
The first enantioselective synthesis of manoalide 124 was accomplished by Soriente et al. 
nearly twenty years after its isolation (Scheme 1.21).204 The alkyl iodide 131 was prepared 
from β-ionone 130 utilizing the same synthetic procedure first reported by Hoffmann et al.201 
The second subunit 129 bearing the stereogenic centre with the desired (R)-configuration was 
prepared in two steps as illustrated in Scheme 1.21.  
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Scheme 1.21: First enantioselective synthesis of (+)-manoalide 124 reported by Soriente et 
al.204 
 
The stereogenic centre at C(4) was introduced by exploiting an aldol condensation 
reaction.206 Subjecting 3-furylaldehyde 92 and silyloxydiene 128 to a mixture of Ti(Oi-Pr)4 
and (R)-BINOL gave the corresponding aldol (65% yield, 88% ee), which was subsequently 
converted to its corresponding ester 129 by microwave irradiation (Scheme 1.21).206  
The alkylation reaction between homoallyl iodide 131 and the ester 129 required the 
presence of tetrabutylammonium salt 132 as a phase transfer catalyst to furnish, after 
diastereoselective ketone reduction, furan 133. An ensuing three-step protocol generated 
lactone 134 via ester hydrolysis, acetylation with simultaneous lactonization and finally 
elimination of acetate in the presence of DBU. Treatment with DIBAL-H to afford the lactol 
followed by photooxygenation of the furan moiety successfully furnished (+)-manoalide 124 
(Scheme 1.21).  
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Four years later in 2003, Kocienski et al. reported the second enantioselective synthesis of 
(+)-manoalide 124 (Scheme 1.22).205 In contrast to Sodano’s methodology, the stereogenic 
centre was introduced using a Sharpless kinetic resolution. Similar to Sodano’s synthesis, 
Kocienski’s route employed the same homoallyl iodide 131, which was prepared from β-
ionone 130 but using a different 8 step procedure.  
 
 
 
Scheme 1.22: Second enantioselective synthesis of (+)-manoalide 124 reported by Kocienski 
et al.205 
 
The second subunit was derived from furyl aldehyde 135, which was reacted with propargyl 
magnesium bromide to afford a racemic propargylic alcohol. Sharpless asymmetric 
epoxidation of the alcohol subsequently afforded the desired (R)-configured alcohol 136 in 
41% yield. Successive Mo-catalysed cycloisomerisation in the presence of Bu3SnOTf led to 
the vinyl stannane 137, which is the key intermediate for the Cu-mediated 1,2-metalate 
rearrangement. To facilitate this cross coupling reaction, the vinyl lithium species of 137 was 
generated in-situ using s-butyllithium, which was subsequently added to the mixed cuprate 
138 previously prepared from homoallyl iodide 131 employing t-butyllithium and 1-
pentynylcopper. The vinyl cuprate species was quenched with iodine to generate vinyl iodide 
139. The last three steps in the synthetic route involved a palladium-catalysed carbonylation 
reaction to afford a lactone, which was subsequently reduced to its corresponding lactol using 
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DIBAL-H. Similar to Sodano et al., the final step was a photooxidation of the furan moiety 
using rose bengal to furnish (+)-manoalide 124 (Scheme 1.22).   
Manoalide 124 was licensed to Allergan Pharmaceuticals and reached phase II clinical trials 
as a topical antipsoriatic. Its development was however discontinued due to formulation 
problems. The compound is now commercially available as a biochemical standard tool to 
block the action of PLA2.207,208  
 
With regard to the first synthesis of (E)-neomanoalide 126 and (Z)-neomanoalide 127, this 
was first achieved by Jefford and Boukouvalas et al. in 1994.209 Charles Jefford and John 
Boukouvalas have been involved in the synthesis of a number of synthetically novel 
furanolipid marine natural products in the last two decades. With respect to the the early 90’s, 
they applied versatile furanolate technology which worked efficiently for the synthesis of γ-
lactone and furan natural products like freelingnite,210 (+/-)-eldanolide and 
siphonodictidine.211,212 Logically, this methodology, which is illustrated in Scheme 1.23, was 
again utilised in the concise synthesis of (E)-neomanoalide 126 and (Z)-neomanoalide 127.  
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Scheme 1.23: Concise synthesis of (E)-neomanoalide 126 and (Z)-neomanoalide 127 as 
developed by Jefford et al.209 
 
The key step in preparation of (E)-neomanoalide 126 and (Z)-neomanoalide 127 involved 
attachment of the two coupling partners 147 and 149. This was achieved by generating the 5-
lithio derivative of 149 using tert-butyllithium and subsequent cross coupling with 147. 
Furan 149 was prepared from the γ-lactone 148 by treatment with (tert-butyl)dimethylsilyl 
trifluoromethanesulfonate in the presence of triethylamine.  
 
Preparation of the allyl bromide 147 was accomplished by modifying and extending the side 
chain of (E)-methyl monocyclofarnesate 140 (Scheme 1.23). Reduction and bromination of 
140 gave the bromide 142. The hydroxy acetone element of the molecule was attached by 
employing hydrazone 143. The anion of 143 was generated in-situ by the action of lithium 
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diisopropylamine and alkylated with 142 to give hydrazone 144. Hydrolysis with copper 
acetate gave the ketone 145 which was submitted to a Wittig reaction with ethyl 
(diethoxyphosphoryl)acetate to furnish both the 2E and 2Z-isomers of ethyl ester 146 in a 1:1 
ratio, which were separated by column chromatography. Each isomer was converted 
separately to its corresponding (2E)- and (2Z)-bromide 147 (Scheme 1.23).  
Following attachment of the two coupling partners 147 and 149, hydrolysis with aqueous 
hydrochloric acid successfully delivered (Z)-neomanoalide 127 or (E)-neomanoalide 126 
depending on the isomer of 147 employed (Scheme 1.23). 
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1.1.9.3 Summary  
Herein, I have reported on the total synthesis of a variety of biologically active 
sesterterpenoid marine natural products of varying complexity ranging from simple linear 
furanolipid molecules like furospinosulin-1 69 to more complex molecules containing 
stereogenic centers and cyclic systems like (-)-ircinianin 104 and (+)-wistarin 105. All 
syntheses reported in this section feature much of the repertoire of modern chemistry, 
including elaborate intramolecular Diels-Alder reactions and exciting transition-metal 
catalysed C-C-bond formations and rearrangements. As we reflect on the syntheses featured 
in the section, a number of plausible methods to achieve the concise total synthesis 
furospongolide 55 have been identified. Elegant concepts for introducing the furan and 
butenolide ring onto a central linchpin unit have been discussed as well as exciting and 
convenient functional group transformation reactions. These reactions will all be considered 
as practical approaches towards the synthesis of our target molecule 55. 
 
Despite the uniqueness of each sesterterpenoid reported in this section, they all have a 
common structural homology containing either/both a furan or lactone ring, which must at 
some level be connected to their inherent biological activity. This comparative study between 
sesterterpenoids provided promising concepts on how to amend the structure of 
furospongolide 55 to increase its potency as an antitumour agent. Standard oxidation and 
reduction chemistry can also be performed on our target molecule 55 to alter its structure to 
imitate other known biological active marine natural products. 
As new members of the sesterterpenoid family are continually being discovered, and largely 
forgotten ones unearthed, modern synthetic chemistry will continue to be developed and 
refined to meet the needs for synthetically targeting these important and attractive molecules 
of this fascinating class of natural products.     
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HETCOR   heteronuclear correlation 
HMBC    heteronuclear multiple bond correlation 
HPLC    high performance liquid chromatography 
HRMS    high resolution mass spectrometry 
HSQC    heteronuclear single quantum correlation 
Hz     hertz 
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